The FDA approved expanded use of Auvelity, an extended release major depressive disorder drug, for use in the treatment of Alzheimer disease.

Glucagon-like peptide-1 receptor agonists have been identified as a potential novel treatment for alcohol use disorder.

Maternal abuse history significantly increases the risk for social-emotional delay in children at age 3 years.

LB-102 vs placebo significantly improved PANSS total scores in adults with acute exacerbation of schizophrenia.

Non-tobacco nicotine use before pregnancy increased the risk for preterm labor, cesarean delivery, and various maternal complications.

What social risk factors affecting your patients may affect their risk of major depressive disorder more than they realize?

The FDA has updated the label for Caplyta to include phase 3 data showing a significant reduction in schizophrenia relapse risk.

Among young adults newly diagnosed with cancer, a problem-solving skills intervention was effective for reducing depression and anxiety.

The APA proposed new DSM revisions to incorporate socioeconomic, cultural, and environmental determinants into diagnostic ...

In positive vs negative affect treatment, patients with moderate-to-severe depression or anxiety benefited more.

A new study identified 3 trajectories for preclinical Alzheimer disease progression, categorizing the condition by projected stability.

Demographic differences in opioid prescribing after hysterectomy occurred following ERAS adoption but resolved after targeted quality improvement measures.